人类诺亚上腺素载体再吸收和抑制的分子基础
Jiaxin Tan1, Yuan Xiao1, Fang Kong1
1Beijing Frontier Research Center for Biological Structure, State Key Laboratory of Membrane Biology, Tsinghua-Peking Joint Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China.
Nature
|July 24, 2024
概括
研究人员揭示了人类的诺亚特上腺素载体 (NET) 结构,详细说明了像诺亚特上腺素和多巴胺这样的基质如何结合. 该研究还显示了四种抗抑郁药如何阻断NET功能,为其机制提供了洞察力.
科学领域:
- 神经科学是一个神经科学.
- 结构生物学 结构生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 诺拉丁上腺素 (norepinephrine) 影响许多大脑细胞类型.
- 上腺素运输体 (NET) 对于上腺素从突触裂清除至关重要.
- 了解NET的结构和功能是开发有效抗抑郁药的关键.
研究的目的:
- 为了确定人体NET的冷电子显微镜 (cryo-EM) 结构.
- 阐明基质和抗抑郁药对NET的结合机制.
- 揭示抗抑郁药对NET抑制的功能和机制细节.
主要方法:
- 使用冷电子显微镜 (cryo-EM) 来获得人类NET的高分辨率结构.
- 结构被确定在apo状态和复合与基质 (诺阿德拉林,多巴胺) 和抗抑郁药物 (阿托莫克赛丁,脱胺,布罗,埃斯基塔洛普拉姆).
- 结构数据被生化分析补充.
主要成果:
- 人类NET的冷EM结构以2.53.5 Å的分辨率得到分辨.
- 诺拉丁上腺素和多巴胺在中央 (S1) 和新发现的全性 (S2) 部位中具有相似的结合方式.
- 四种抗抑郁药与S1部位结合,通过不同的形状阻碍基质运输;在特定条件下,在结合部位观察到离子.
结论:
- 该研究提供了详细的结构洞察力,了解人体NET的基质识别和传输机制.
- 抗抑郁药的独特结合方式阐明了它们在抑制NET的作用机制.
- 这些发现提升了我们对NET功能和抗抑郁药物药理学的理解.
相关概念视频
Drugs Affecting Neurotransmitter Release or Uptake
1.0K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.0K
Adrenergic Neurons: Neurotransmission
3.6K
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which...
Synthesis: Catecholamine synthesis requires tyrosine, which...
3.6K
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
Adrenergic Agonists: Indirect-Acting Agents
1.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.6K
Adrenergic Receptors: ɑ Subtype
1.5K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.5K
Adrenergic Receptors: β Subtype
1.6K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.6K


